China's New Exit Rule: S-Funds, Not Just IPOs, to Free $1.7T in VC Cash

China's Central Cyberspace Affairs Commission published a five-year action plan for cyberspace enterprises at roughly 8 p.m. Beijing time on August 21. Article 19 of the plan, under financial support, does two things at once: it tells regulators to speed up domestic IPO reviews and keep encouraging listings on the STAR Market and ChiNext, and it tells the market to build out private-equity secondary funds (S-funds) and M&A funds as routes to exit that don't require a listing at all.

Read against the underlying numbers, it is the clearest national signal yet that China's venture-capital machine has an exit problem the IPO market alone cannot solve.

A backlog too large for one exit door

By the end of January, RMB12.51 trillion sitting inside Chinese private-equity and venture funds was already in exit or extension phases, according to Zero2IPO data — RMB7.67 trillion formally exiting, RMB4.83 trillion granted extra time. A separate CVSource count puts more than 66,000 privately financed companies in limbo, with almost half of them unfunded for over five years.

Against that stock, China's entire secondary market — where fund investors sell stakes to someone else rather than wait for an IPO — processed just RMB117.9 billion in 2025, a record year, per data provider ZERONE/执中. First-half 2026 volume fell to RMB31.6 billion, partly because rising public valuations widened the gap between seller expectations and buyer bids. A single door cannot drain a reservoir this size on any reasonable timetable.

A different buyer shows up

What has changed in 2026 is who shows up to buy. Among newly registered S-funds in the first half, state and government capital supplied about 45% of commitments and insurance capital about 41% — up from roughly 3% a year earlier. Asset-management companies went from 1.4% to 34.8% of financial-institution buying volume. Concrete deals back this up: China Life committed RMB2.8 billion to a technology-focused continuation fund, Zhonghui Life put RMB1.145 billion into a Yunfeng-linked vehicle, and New China Life invested RMB500 million through CPE. Insurers, with liabilities stretching decades, are a natural match for aging venture stakes that take years to reach fair value.

Shanghai already tested the mechanics

Much of this had a dress rehearsal. In April, Shanghai's state-assets regulator let state-owned sellers price fund-interest transfers using independent, market-based valuations rather than book value alone, and pushed its local exchange to publish trading data. The effect was immediate: the platform's January–April transaction value came in more than ten times higher than the year before, admittedly from a small base. The unresolved problem the reform targets is real — officials overseeing state capital have historically avoided selling below reported net asset value for fear of being accused of squandering public funds. Without that fix, subsidized buyers alone cannot generate a market.

The public market backdrop

Chinese equities are hardly closed for business. STAR 50 finished August 21 essentially flat and ChiNext 50 rose 1.87%, before the CAC plan was even published. STAR is up roughly 23% for the year. IPO applications rose 37% year over year in the first half, and 109 venture-backed companies completed listings. A functioning IPO channel still cannot process a twelve-trillion-yuan backlog on the schedule fund maturities demand.

Who is actually buying matters more than the policy text

Foreign private-equity firms among the world's ten largest announced zero new mainland deals in the first seven months of 2026. Filling that space is a distinctly domestic set of institutions — state guidance funds, insurers, asset-management companies — each absorbing a slice of risk that Chinese venture capital once handed to public markets or overseas buyers.

For anyone allocating capital into China's technology sector, this reframes the timing question executives usually ask. Waiting for an IPO window is a narrower bet than tracking which regulated domestic balance sheet will hold a stake for the next decade, at what price, and under what valuation rules. Shanghai's pricing framework and China's insurance-allocation rules deserve as much attention as the STAR Market's index level, since that is where the next liquidity event gets decided.

not investment advice

Sources: https://www.xinhuanet.com/20260821/d97d353ee96946af94251b6912992ee4/c.html